Supriya Lifescience delivers robust Q3 FY26 performance with 11% YoY revenue growth
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
Motorica India conducted a specialised masterclass led by Shumaev, centred on real-life rehabilitation scenarios and personalised therapy programs before and after prosthetic fitting
The unveiling marks Time Medical India’s entry into next-generation helium-free MRI technology
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy
Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates
Subscribe To Our Newsletter & Stay Updated